Jnana launch­es with $50M to spot­light an un­ex­plored pro­tein ter­ri­to­ry

Boston start­up Jnana Ther­a­peu­tics is launch­ing with a $50 mil­lion Se­ries A round to de­vel­op a drug dis­cov­ery plat­form it hopes will push the en­ve­lope of pro­tein sci­ence.

The com­pa­ny is look­ing to dis­cov­er on­col­o­gy tar­gets (among oth­er dis­ease ar­eas) by in­ves­ti­gat­ing how pro­teins known as SLC trans­porters func­tion across cells and in tis­sues.

“These pro­teins are amongst the old­est in bi­ol­o­gy, and af­ford av­enues to ad­dress vir­tu­al­ly all ma­jor dis­eases,” said the com­pa­ny’s CEO Amir Nashat in a state­ment. “Af­ter 50 years of drug de­vel­op­ment, on­ly a hand­ful of SLCs have been har­nessed to treat dis­ease, leav­ing over 400 mem­bers un­stud­ied.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.